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Allogeneic hematopoietic cell transplantation (HCT) following
nonmyeloablative conditioning has been extensively evaluated
in patients with hematologic malignancies who are ineligible for
conventional HCT because of age or medical comorbidities.
Nonmyeloablative regimens have led to an initial state of mixed
hematopoietic chimerism defined as coexistence of donor- and
host-derived hematopoiesis. While nonmyeloablative regimens
have been associated with reduced regimen-related toxicities in
comparison with conventional myeloablative conditioning,
graft rejection, graft-versus-host disease (GVHD), and disease
progression have remained significant challenges. In this
article, after briefly introducing current techniques for chimer-
ism assessment, we describe factors affecting donor chimer-
ism levels after nonmyeloablative conditioning, and then review
data suggesting that chimerism assessment early after HCT
might help identify patients at risk for graft rejection, GVHD and
relapse/progression. Finally, we discuss how these observa-
tions have opened the way to further research protocols
evaluating manipulation of postgrafting immunosuppression,
and/or infusion of donor immune cells.
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Introduction
In Greek mythology, the ‘Chimera,’ as described by Homer, was
a fire-breathing monster with the head of a lion, the body of a
goat and the tail of a serpent, who terrorized the land of Lycia
before being eventually killed by Bellerophon. Three thousand
years later, the term ‘chimerism’ was introduced in the field of
medicine by Anderson et al.1 to describe ‘organisms whose cells
derive from two or more zygote lineages.’ In hematopoietic cell
transplantation (HCT), chimerism refers to the presence of
lympho-hematopoietic cells of donor origin after an allogeneic
HCT. For practical reasons, the term ‘complete or full (donor)
chimerism’ has been defined as 495% of cells of donor origin,
while the term ‘mixed chimerism’ is used to describe patients
with 5–95% cells of donor origin in hematopoietic tissues2
(Table 1).
Mixed chimerism was first described in patients with
advanced acute leukemia3 or severe aplastic anemia4,5 condi-
tioned with high-dose cyclophosphamide, with or without
added antithymocyte globulin (ATG). In patients with aplastic
anemia, mixed host/donor chimerism was associated with
higher risk of graft rejection, but lower incidence of acute
graft-versus-host disease (GVHD).4,5 Stable mixed chimerism
was also found in some patients with hematologic malignancies
given unmodified marrow grafts after myeloablative condition-
ing, although its impact on HCT outcomes remained contro-
versial.5–8 Further, initial mixed chimerism was frequently
observed among patients receiving T-cell-depleted marrows
after myeloablative conditioning,9–11 indirectly evincing that the
recipients’ lympho-hematopoiesis was destroyed not only by the
conditioning regimens but also by donor immunocompetent
cells contained in the grafts (graft-versus-host effects), even after
myeloablative conditioning. Finally, mixed donor/host chimer-
ism in T-cells, a compartment that has not been involved in the
neoplastic process in chronic myeloid leukemia, was shown to
be an independent marker for subsequent disease relapse in
patients with chronic myeloid leukemia given T-cell-depleted
marrows after myeloablative conditioning,12 suggesting that
mixed donor/host T-cell chimerism reduced graft-versus-tumor
effects.
Reduced-intensity or truly nonmyeloablative conditioning
regimens followed by allogeneic HCT have been increasingly
used in patients with hematologic diseases who are not
considered candidates for conventional HCT because of age,
medical comorbidities, or prior failed myeloablative HCT, and
in selected patients with solid tumors (recently reviewed in
references13–15). Those regimens have relied mainly on the
immune-mediated graft-versus-tumor effects for tumor eradica-
tion.16–22 Criteria for nonmyeloablative conditioning as first
proposed by Giralt and Champlin have included: (1) no
eradication of host hematopoiesis, (2) prompt hematologic
recovery (o4 weeks) without HCT and (3) presence of mixed
chimerism upon engraftment.23,24 The criteria determining
whether a conditioning regimen is nonmyeloablative versus
reduced in intensity have been somewhat arbitrary and
controversial.25 The distinction might be clinically meaningful
given that a recent study from the MD Anderson Cancer Center
demonstrated that nonmyeloablative conditioning is associated
with increased risk of secondary graft rejection, decreased risk of
nonrelapse mortality, and perhaps higher risk of relapse in
comparison with reduced-intensity regimens.26 In addition,
while initial mixed chimerism was observed in most patients
given nonmyeloablative conditioning,27–30 many patients given
grafts after reduced-intensity conditioning achieved full donor
T-cell and granulocyte chimerism as early as 14 days after
HCT.31 In this review, after briefly introducing current methods
for chimerism assessment, we describe factors affecting donor
chimerism levels after nonmyeloablative conditioning, and then
review data suggesting that chimerism assessment early after
HCT might help identify patients at risk for graft rejection,
GVHD, and relapse/progression. Finally, we discuss how these
Received 7 April 2006; revised 1 June 2006; accepted 13 June 2006;
published online 27 July 2006
Correspondence: Dr BM Sandmaier, Fred Hutchinson Cancer Re-
search Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle,
WA 98109-1024, USA.
E-mail: bsandmai@fhcrc.org
Leukemia (2006) 20, 1690–1700










observations have opened the way to further research protocols
evaluating manipulation of postgrafting immunosuppression,
and/or infusion of donor immune cells in patients with low
donor chimerism levels.
Current methods for chimerism analyses
Several methods have been developed to assess the level of
donor engraftment after allogeneic HCT (for excellent reviews
see references1,32–34). Early methods were based on analyses of
erythrocyte antigens, leukocyte isoenzymes or conventional
cytogenetics. However, these methods were time consuming,
and/or had limited sensitivity and quantitative accuracy
(Table 2). In the 1980s, methods based on restriction fragment
length polymorphisms (RFLP) analysis were developed,10 but
were progressively abandoned, in part due to the large amounts
of DNA required.1,32,33 Currently, fluorescent in situ hybridiza-
tion of sex chromosomes (XY-FISH) and polymerase chain
reaction (PCR)-based analysis of polymorphic DNA sequences
(such as variable number of tandem repeats (VNTR) or short
tandem repeats (STR)) are the most widely used techniques,
while real-time PCR techniques based on analysis of the
Y chromosome or on single nucleotide polymorphism (SNP)
are increasingly evaluated.1,32,33
XY-FISH
XY-FISH has remained widely used to assess degrees of donor
engraftment after HCT.35 The strengths of this technique are a
high-sensitivity (o1%), and a quantitative accuracy better than
what is achievable with most PCR-based assays.32 Unfortu-
nately, this technique can only be used in sex-mismatched HCT.
Other limitations include loss of the Y chromosome observed in
cells from older males, and in some tumor cells.32
VNTR- or STR-PCR
Some core DNA sequences are tandemly repeated in the
genome.36 The number of such tandem repeats varies among
individuals and are inherited as codominant Mendelian
traits.32,33 Repeats can be composed of sequences of 8–100 bp
in length (VNTR or ‘minisatellites’), or of sequences of 2–8 bp in
length (STR or ‘microsatellites’).32 VNTR and STR markers have
an advantage over XY-FISH in that they can be used for virtually
all donor–recipient pairs.37 In addition, when used in combina-
tion with DNA amplification by PCR, only a small number of
cells (o1000) are required for the test.38 For quantification, PCR
products are electrophoresed on agarose gels,36 hybridized with
32P-labeled probes, autoradiographed and quantitated by
phosphorimaging,30 or PCR is carried out with fluorescently
labeled primers and the PCR product then visualized, for
example, using the ABI 310 sequencer (Applied Biosystems,
Foster City, CA, USA).37,39 Results obtained with STR or VNTR
markers appear to be similar.40 The sensitivity of STR analyses
has been limited by slipped-strand mispairing of product and
template strands during PCR (stutter peaks), which might induce
overlap of donor and recipient alleles, and which are more
frequent with smaller repeat length. Thus, depending on
fragment length and efficiency of amplification, the sensitivity
of VNTR- or STR- PCR ranges from 1 to 5%, but can approach
0.1% in favorable cases.32,33 STR-PCR technique has been
further improved by amplification of different loci in a single
multiplex reaction,37,38 and quantitative accuracy with multi-
plex PCR has approached that using XY-FISH.38
Real-time PCR
While XY-FISH and multiplex STR-PCR have been successful
techniques for accurately assessing chimerism levels, and are
currently the techniques of choice to monitor T-cell chimerism
Table 1 Definitions
Term Definition
Graft rejection o5% of T-cells of donor origin
Mixed T-cell chimerism 5–95% of T-cells of donor origin
Full (complete) donor T-cell
chimerism
495% of T-cells of donor origin
Increasing T-cell chimerism Increasing percentage of T-cells
of donor origin
Table 2 Methods for determining chimerism.
Assay (reference) Sensitivity (%) Quantitative accuracy Disadvantages
Erythrocyte antigens32 0.1–0.5 Moderate Studies limited to the erythroid lineage
Cytogenetics32 10–20 Low Low sensitivity/accuracy
Studies limited to cells in metaphase
HLA antigens93,94 Variable Variable Limited to HLA-mismatched pairs
Reagents able to specifically detect many of the
HLA-alleles are not yet available
FISH32,33 0.1–2 Very-high Only available for sex-mismatch HCT (or when an
informative autosomal marker is present).
Y chromosome loss in tumor cells and with aging
RFLP1,32 5–20 Moderate Technical difficulty
Moderate sensitivity/quantitative accuracy
High DNA requirement




1–5 Higha Moderate sensitivity
Real-time PCR1,33,34 0.001–1 Moderate Moderate quantitative accuracy
FISH, fluorescent in situ hybridization; HCT, hematopoietic cell transplantation; HLA, Human leucocyte antigen; PCR, polymerase chain reaction;
RFLP, restriction fragment length polymorphisms; STR, short tandem repeats; VNTR, as variable number of tandem repeats.
aWhen multiplex PCR approaches are used.
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after nonmyeloablative or reduced-intensity conditioning, it has
been thought that a sensitivity between 1 and 5% is insufficient
to detect (increasing) minimal residual disease and to predict
imminent relapse after myeloablative conditioning. One ap-
proach to overcome this limitation has been to isolate the
population of interest (for example CD34þ cells in patients
with acute leukemia, CD138þ cells in patients with multiple
myeloma, or CD19 cells in patients with chronic lymphocytic
leukemia) by flow cytometry or immunomagnetic selection, and
to perform XY-FISH or STR-PCR in this selected cell subpopula-
tion.32,41,42 This strategy may increase significantly the sensitiv-
ity of the assay, allowing pre-emptive therapy with DLI and/or
targeted agents.33,43 Another approach consists of using real-
time PCR amplification of DNA polymorphisms. As only unique
DNA sequences are useful for real-time PCR, repetitive DNA
polymorphisms like VNTR or STR cannot be used. Thus, several
other markers have been investigated, including Y chromosome
markers, single nucleotide polymorphisms (SNP), and short
insertion/deletion polymorphisms.44–46 The sensitivity of these
techniques ranges from 0.0001 to 0.1%, probably allowing
minimal residual disease quantification in patients given myelo-
ablative conditioning or in patients given nonmyeloablative
conditioning after they achieve 100% donor T-cell chimerism.
However, despite recent improvements, the quantitative accu-
racy of real-time PCR has remained below what is achieved with
XY-FISH or multiplex PCR.33
Kinetics of donor blood cell subsets engraftment
While nonmyeloablative conditioning usually leads to an initial
state of mixed chimerism, only a few reports have analyzed the
engraftment kinetics of specific hematopoietic lineages after
nonmyeloablative conditioning. Childs et al.27 studied chimer-
ism evolution among various blood cell subsets in 15 patients
given allogeneic HCT after conditioning with fludarabine
(125 mg/m2) and cyclophosphamide (120 mg/kg). Postgrafting
immunosuppression consisted of cyclosporine (CSP) alone. The
patterns of engraftment varied among their patients, but most
often full donor chimerism was achieved earlier in T cells
(CD3þ , median time 30 (range, 14–164) days) than in myeloid
cells (CD14/15þ ). Chimerism levels among blood myeloid
cells correlated with those observed among marrow progenitor
cells (CD34þ , r¼ 0.99), and erythroid (CD71þ , r¼ 0.98) cells.
Similarly, chimerism levels among blood T-cells closely
correlated with those observed among blood NK cells (defined
as CD2þCD3- cells, r¼ 0.98). In contrast, B-cell (CD19þ
cells) recovery was distinct from both myeloid (r¼ 0.26) and
T-cell lineages (r¼ 0.24).
We analyzed the kinetics of donor engraftment in peripheral
blood hematopoietic subpopulations from 120 patients condi-
tioned with 2 Gy TBI with or without fludarabine (90 mg/m2),
and postgrafting immunosuppression with mycophenolate
mofetil (MMF) and CSP.30 While patients rapidly developed
high degrees of donor engraftment, most remained mixed donor/
host chimeras for up to 3–6 months after HCT. Correlations
between donor T-cell content and those of granulocytes
(r¼ 0.37), NK cells (r¼ 0.66) and monocytes (r¼ 0.56) were
relatively weak.
Factors affecting chimerism levels after reduced-intensity or
nonmyeloablative conditioning
Several factors have been associated with kinetics of donor
engraftment after nonmyeloablative or reduced-intensity
conditioning. These factors influence either the recipients’
immune competence (thereby affecting host-versus-graft (rejec-
tion) reactions), the immune competence of the cells in the graft
(thereby affecting graft-versus-host reactions), or both.
Factors affecting host-versus-graft reactions
Conditioning regimen. Not surprisingly, the intensity of the
conditioning regimen has affected the speed of donor engraft-
ment. In a preclinical canine model of nonmyeloablative
transplantation, decreasing doses of TBI (from 2 to 0.5 Gy) are
associated with lower donor chimerism levels.47,48 In humans,
the addition of fludarabine (90 mg/m2) or autologous HCT
(tandem autologous-allogeneic HCT) to a 2 Gy TBI conditioning
is associated with higher donor T-cell chimerism levels early
after HCT (P¼ 0.001).49 Further, comparing chimerism levels in
patients given peripheral blood stem cells (PBSC) from related
donors as treatment for metastatic solid tumors after different
conditioning regimens, median day-28 donor T cell and
myeloid chimerism levels were 100 (range, 100–100)% and
100 (range, 100–100)% in patients conditioned with fludarabine
(125–150 mg/m2) and melphalan (140 mg/m2),31 versus 92
(range, 55–100)% and 38 (range, 5–97)% in patients condi-
tioned with fludarabine (125 mg/m2) and cyclophosphamide
(120 mg/kg),29 versus 71 (range, 50–90)% and 91 (range,
60–99)% in patients conditioned with fludarabine (90 mg/m2)
and 2 Gy TBI,50 respectively.
Previous chemotherapy. Valcarcel et al. analyzed data
from 68 patients transplanted after conditioning with fluda-
rabine (150 mg/m2) and busulfan (10 mg/kg) (patients with
myeloid malignancies, n¼ 28), or with fludarabine (150 mg/
m2) and melphalan (140 mg/m2) (patients with lymphoid
malignancies, n¼ 40).51 In multivariate analysis, having re-
ceived more than two lines of chemotherapy pretransplant was
the only factor significantly associated with achievement of
complete donor chimerism among unfractionated nucleated
peripheral blood cells at day 30 after HCT (P¼ 0.02). Similarly,
Carvallo et al.,29 analyzing data from 36 patients with solid
tumors given allogeneic grafts after fludarabine (125 mg/m2) and
cyclophosphamide (120 mg/kg), found that T cell (P¼ 0.008)
and granulocyte (Po0.0001) donor chimerism levels were
higher in patients previously given myelosuppressive che-
motherapy in comparison to patients who were not given
chemotherapy. Consistent with these observations, myelosup-
pressive chemotherapy received before HCT was associated
with higher donor T cell (P¼ 0.002), granulocyte (P¼ 0.002),
monocyte (P¼ 0.01) and NK (P¼ 0.10) chimerism levels in a
study analyzing data from 120 patients given grafts from related
or unrelated donors after 2 Gy TBI with or without fludarabine
(90 mg/m2).30
Underlying disease category. Lower levels of donor
chimerism and higher incidences of graft rejection have been
observed in patients with chronic myeloid leukemia or
myelodysplastic syndrome, in comparison to patients with other
hematologic malignancies.18,52–56 Whether this is due to the
fact that most of these patients were not given myelosuppressive
chemotherapy before the HCT procedure, or whether the reason
was the underlying diseases themselves (e.g., by inhibitory
effects of myelodysplastic cells on donor hematopoiesis57)
remains unclear. For example, patients with chronic myeloid
leukemia or myelodysplastic syndrome were found to have
lower levels of donor T-cell chimerism than patients with acute
myeloid leukemia or with lymphoid malignancies (P¼ 0.03) in a
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study analyzing engraftment kinetics after 2 Gy TBI with or
without fludarabine (n¼ 120).30 However, after adjusting for
prior myelosuppressive chemotherapy or not, the impact of
disease category on donor T-cell chimerism levels was no longer
significant.
Factors affecting graft-versus-host reactions
Stem cell source. Maris et al.53 analyzed outcomes of
patients given unrelated marrow versus unrelated PBSC after
fludarabine and 2 Gy TBI. Marrow recipients had lower levels of
donor T-cell chimerism the first 2 months after HCT (Po0.02),
higher incidence of graft rejection (P¼ 0.007), and worse
progression-free survival (P¼ 0.006). In contrast with these
observations, full donor chimerism was achieved rapidly in
many patients given marrows after more intense (but still
‘reduced intensity’) conditioning regimens.56,58
PBSC composition. The first study analyzing the impact of
PBSC composition on donor chimerism levels was reported by
Carvallo et al.29 The authors showed that high levels of CD34þ
progenitor cells in the grafts were associated with higher levels
of donor myeloid chimerism early after HCT. However, no
significant correlations between graft composition and donor
T-cell chimerism levels were observed. We analyzed the impact
of graft composition on HCT outcomes in 125 patients given
PBSC from HLA-identical siblings after 2 Gy TBI with or without
fludarabine.49 Higher number of NK cells transplanted was
associated with higher levels of day-28 donor T-cell chimerism
(P¼ 0.03). Cao et al., using the same preparative regimen
combining 2 Gy TBI with or without fludarabine, showed that
higher numbers of transplanted CD8þ T-cells correlated with
increased donor T-cell chimerism levels on day 28 after HCT
(P¼ 0.009), and greater likelihood for achievement of full donor
T-cell chimerism (P¼ 0.03) in a study analyzing combined
observations in 63 patients given PBSC from either related
(n¼ 38) or unrelated (n¼ 25) donors.59 Finally, we analyzed the
impact of graft composition on HCT outcomes among 116
patients receiving PBSC from HLA-matched unrelated donors
after conditioning with fludarabine and 2 Gy TBI.60 High
numbers of donor T-cells (P¼ 0.03), CD4þ T-cells
(P¼ 0.007), CD8þ T-cells (P¼ 0.29), NK cells (P¼ 0.04) and
CD34þ progenitor cells (P¼ 0.01) in the graft were each
associated with high levels of day-28 donor T-cell chimerism.
Furthermore, high numbers of CD34þ cells in the graft were
associated with faster achievement of full donor T-cell chimer-
ism (P¼ 0.02). Taken together, these data suggest that higher
numbers of each CD34þ progenitor cells and immune (T-cells
and NK cells) cells in the grafts increase donor chimerism levels
after nonmyeloablative conditioning.
Factors affecting host-versus-graft and graft-versus-host
reactions
Postgrafting immunosuppression. Maris et al.61 compared
day-28 donor T-cell chimerism levels among patients receiving
HLA-matched unrelated PBSC after nonmyeloablative condi-
tioning with 2 Gy TBI and fludarabine, and given CSP plus MMF
15 mg/kg twice a day (bid group, n¼ 71) versus MMF 15 mg/kg
thrice a day (tid group, n¼ 103) as postgrafting immunosuppres-
sion. Median donor T-cell chimerism levels on day 28 after HCT
were 75% in the bid group, versus 92% in the tid group
(P¼ 0.02). In agreement with these findings, Giaccone et al.62
observed a positive correlation between mycophenolic acid (the
active metabolite of MMF) concentration steady-state levels on
days 7 and 21 after HCT, and donor T-cell chimerism levels
28–84 days after HCT (P¼ 0.04), in patients given unrelated
grafts after fludarabine and 2 Gy TBI, and postgrafting immuno-
suppression with MMF and CSP.
Associations between engraftment kinetics and HCT
outcomes
Graft rejection
Nonfatal graft rejection has remained a significant complication
of HCT following nonmyeloablative or reduced-intensity con-
ditioning in patients with chronic myeloid leukemia or
myelodysplastic syndrome receiving grafts from unrelated
donors.54,56 This has prompted several groups of investigators
to look whether donor chimerism levels early after HCT could
predict graft rejection.
Bornhauser et al.52 first observed that patients with NK-cell
donor chimerism levels below 75% on days 10–30 after
unrelated HCT following conditioning with fludarabine
(150 mg/m2) intraveneous (i.v.) busulfan (6.6 mg/kg), and ATG
were more likely to have graft failures (three of three patients)
than those with more than 75% (one of seven patients, P¼ 0.03).
Data from Matthes-Martin et al.63 confirmed this observation by
showing graft rejection in nine of 15 children (given various
reduced-intensity conditioning) witho100% donor NK-cells on
day 28 after HCT versus 0 of 24 children with 100% donor NK
cell chimerism on the same day (Po0.0001).
We recently observed that day-14 T-cell and NK cell donor
chimerism levels below 50% were each associated with
increased risks of subsequent graft rejection (P¼ 0.0007 and
P¼ 0.003, respectively) in a study analyzing data from 157
patients given grafts after 2 Gy TBI with or without fludarabine
(Baron F et al., Biol Blood Marrow Transplant 2005, 11(Suppl):
31 (abstract)). Specifically, 50% of patients with donor T-cell
chimerism levels below 25%, 8% of patients with donor T-cell
chimerism levels between 26 and 50%, 4% of those with levels
between 51 and 75%, and 0% of those with levels above 75%
rejected their graft. For NK cell chimerism levels, corresponding
figures were 44, 20, 0 and 4%, respectively (Figure 1a).
Figure 1b shows the cumulative incidence of graft rejection
according to day-28 donor T-cell chimerism levels in a group of
21 patients given unrelated grafts after nonmyeloablative
conditioning as treatment for chronic myeloid leukemia.
Graft-versus-host disease
The intensity of the preparative regimens has been shown to
contribute to acute GVHD physiopathology, presumably by
inducing tissue damage and the release of a ‘cytokine
storm’.64,65 Further, mixed donor/host hematopoietic chimerism
has been associated with decreased risk of GVHD.5,30,43,66,67
Thus, one might expect relatively decreased incidence of GVHD
after nonmyeloablative versus myeloablative conditioning.
Indeed several reports have shown lower incidence of acute
GVHD after nonmyeloablative versus myeloablative condition-
ing,68–72 including one study analyzing age-matched patients
treated in a single institution.68 However, although relatively
less frequent, acute GVHD has remained a frequent complica-
tion of nonmyeloablative HCT, and has been associated with
increased nonrelapse mortality and decreased progression-free
survival.19,73
Several groups of investigators analyzed the relationship
between engraftment kinetics and acute GVHD. Childs et al.27
observed that achievement of full donor T-cell chimerism
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usually preceded grade II–IV acute GVHD in patients condi-
tioned with fludarabine plus cyclophosphamide. In contrast,
Mattsson et al.74 found that 82% of their patients (conditioned
with four nonmyeloablative regimens, including fludarabine,
busulfan, TBI, cyclophosphamide and ATG) had mixed donor/
host T-cell chimerism at the time of onset of acute GVHD. In
agreement with Mattsson’s findings, we found that 83% of
patients were mixed donor/host T-cell chimera at the time of
onset of grade II–IV GVHD in a study analyzing data from 120
patients given related or unrelated grafts after 2 Gy TBI with or
without added fludarabine.30 These apparent discrepancies
were probably related to the different conditioning regimens
used from one study to another.
Another question has been whether or not assessment of
donor chimerism levels early after HCT helped identify patients
at high risk for acute GVHD. McSweeney et al.18 analyzed data
from 45 patients given related PBSC after 2 Gy TBI and found
that patients with higher levels of donor T-cell chimerism on day
28 after HCT were at higher risk for grade II–IV acute GVHD
than patients with lower levels of donor T-cell chimerism, when
chimerism was analyzed as a continuous linear variable
(P¼ 0.03). Similar observations were made by Maris et al.53 in
patients given unrelated grafts after 2 Gy TBI and fludarabine. In
agreement with these observations, Perez-Simon et al.75 found a
trend toward a lower incidence of acute GVHD in patients with
mixed donor T-cell chimerism (17%) compared to patients with
full donor T-cell chimerism (50%, P¼ 0.1) early (days 28 to 56)
after conditioning with fludarabine plus melphalan or fluda-
rabine plus busulfan.
More recently, we analyzed the relationship between
chimerism levels on day 14 after HCT among various blood
subsets and acute GVHD in 157 patients given related or
unrelated grafts after 2 Gy TBI with or without added fludarabine
(Baron F et al., Biol Blood Marrow Transplant 2005, 11(Suppl):
31 (abstract)). High donor T-cell chimerism levels on day 14
(P¼ 0.02) were associated with increased risks of grades II–IV
acute GVHD. Specifically, among patients alive without GVHD
on day 14, 38% of those with donor T-cell chimerism levels
below 50%, 49% of those with levels between 51 and 75%, and
71% of those with levels above 75% had subsequent grade II–IV
acute GVHD.
Taken together, these observations suggested that patients at
higher risk of acute GVHD might be identified early after
nonmyeloablative HCT. However, it should be emphasized, as
shown in Figure 2, that cell subset chimerism analyses have
been less successful in predicting patients at high risk for grade
III–IV acute GVHD than in predicting patients at high risk for
grade II–IV acute GVHD.
Tumor eradication
It has remained controversial whether or not achievement of full
donor T-cell chimerism is mandatory to achieve disease
response in patients given nonmyeloablative conditioning.
Childs et al.27 observed that full donor T-cell chimerism
generally preceded achievement of disease responses in
patients given grafts after fludarabine plus cyclophosphamide.
Figure 2 (a) Cumulative incidence of grade II–IV acute GVHD based
on day-28 donor T-cell chimerism levels in patients given grafts after
2 Gy TBI with or without fludarabine (Po0.0001).19 (b) Cumulative
incidence of grade III–IV acute GVHD based on day-28 donor T-cell
chimerism levels (P¼0.05).19
Figure 1 (a) Day-14 donor T-cell and NK-cell chimerism levels in
patients with or without subsequent graft rejection. All patients were
given grafts after 2 Gy total body irradiation with or without
fludarabine. Triangle indicates sustained engraftment;  indicates
graft rejection (Baron F et al., Biol Blood Marrow Transplant 2005;
11(Suppl): 31 (abstract)). (b) Cumulative incidence of graft rejection
according to day-28 T-cell chimerism levels in patients with chronic
myeloid leukemia given grafts from unrelated donors after 2 Gy TBI
plus fludarabine (90 mg/m2).54
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In contrast, Mattsson et al.74 found that 40% of their patients
(n¼ 30) had mixed donor/host T-cell chimerism at the time of
disease responses. We found comparable findings in 120
patients given related or unrelated grafts after 2 Gy TBI with or
without fludarabine: 19 of 41 (46%) patients who achieved
complete remissions after HCT were mixed donor/host T-cell
chimera when complete remissions were achieved.30 However,
when donor T-cell chimerism levels were modeled as a
continuous linear variable, high levels of donor T-cell chimer-
ism on day 28 after HCT were suggestively associated with
higher probability of achieving complete remissions (P¼ 0.16).
Two reports looked at the association between donor
chimerism levels and achievement of molecular remissions in
patients receiving nonmyeloablative conditioning as treatment
for chronic myeloid leukemia.55,76 Uzunel et al. analyzed 15
patients given grafts after fludarabine (180 mg/m2), busulfan
(8 mg/kg) and ATG. Full donor T-cell chimerism was usually
seen before (n¼ 5; 24–90 (median 40) days), or at the time
(n¼ 4) of molecular remission.76 However, one patient had
molecular remission with mixed T-cell chimerism. The authors
concluded that complete T-cell chimerism was probably not
required to achieve molecular remissions, given the short
interval between conversion to full donor T-cell chimerism
and molecular negativity. We analyzed data from 13 patients
with chronic myeloid leukemia who achieved molecular
remission after conditioning with 2 Gy TBI with or without
fludarabine.55 Eleven of them achieved molecular remission at
the time (n¼ 1), or after (n¼ 10) conversion to full donor T-cell
chimerism, while two patients had molecular remissions 3 and 9
months before conversion to full donor T-cell chimerism,
respectively.
Relapse, nonrelapse mortality and survival
Assessment of donor chimerism levels might help identify
patients at higher risk of relapse after nonmyeloablative/
reduced-intensity conditioning. First, high donor chimerism
levels among immune cells (T-cells and NK cells) might be a
surrogate for high graft-versus-tumor effects. Secondly, chimer-
ism analyses might be useful to detect and quantitate minimal
residual disease after HCT.
Chimerism among immune cells. Keil et al.77 found that
patients with o90% donor T-cell chimerism on day 28 after
nonmyeloablative conditioning were at higher risk of relapse
(55% versus 18%, P¼ 0.04), and had a lower 2-year probability
of progression-free survival (P¼ 0.002) than patients with
X90% donor T-cell chimerism, in a study analyzing data from
38 patients given grafts after 2 Gy TBI and fludarabine (90 mg/
m2). No correlation between donor granulocyte chimerism
levels and outcomes was observed. We prospectively investi-
gated the relationship between kinetics of donor engraftment of
T-cells and NK cells and outcomes in 229 patients (130 with
HLA-matched related donors and 99 with unrelated donors)
conditioned with 2 Gy TBI with or without fludarabine (Baron F
et al., 2005, Blood; 106 (Part 1): 119a (abstract)). High donor
T-cell (P¼ 0.008) and NK cell (P¼ 0.005) chimerism levels on
days 14–42 were both associated with decreased risk of relapse
in time-dependent analyses adjusted for disease risk, while high
levels of donor NK cell (but not T-cell) chimerism were
associated with better overall (P¼ 0.003) and progression-free
(P¼ 0.003) survivals. If confirmed in a larger number of patients,
this observation might lead to the development of protocols
evaluating infusion of donor NK cells78 in patients with low
donor NK cell chimerism levels early after HCT.
Another important clinical question has been whether or not it
is necessary to achieve full donor T-cell chimerism in patients
without measurable disease after nonmyeloablative or reduced-
intensity conditioning to prevent disease relapse.79 Perez-Simon
et al.75 found a trend for a higher relapse risk in patients with
mixed donor/host T-cell chimerism as compared to patients with
complete donor chimerism after conditioning with fludarabine/
melphalan or fludarabine/busulfan. We investigated the impact
of achievement of full donor T-cell chimerism on HCT outcome
in 322 patients given related or unrelated grafts after non-
myeloablative conditioning.19 In multivariate analyses adjusting
for disease risk, comorbidity and tandem autologous/allogeneic
HCT, achievement of full donor T-cell chimerism was asso-
ciated with a significantly lower risk of relapse (HR¼ 0.5,
P¼ 0.002), and a suggestion for a better progression-free
survival. Further, patients with donor T-cell chimerism levels
o75% at day 84 were found to have higher risk of relapse
(HR¼ 0.4, P¼ 0.002) (Figure 3) than patients withX75% donor
T-cell chimerism levels. Comparable results were recently
reported by Mohty et al., who observed higher risk of relapse
(P¼ 0.002) and worse progression-free survival (P¼ 0.06) in
patients who had mixed donor/host T-cell chimerism in
comparison to patients who had full donor T-cell chimerism
on day 90 after reduced-intensity conditioning HCT as treatment
for myeloid malignancies (Mohty M et al., Biol Blood Marrow
Transplant 2006; 12 (Suppl 1): 33 (abstract)).
Chimerism as a marker for minimal residual disease. In
patients receiving truly nonmyeloablative conditioning, chimer-
ism among total blood cells or among myeloid cells in patients
with myeloid malignancies has been a poor marker for minimal
residual disease, and has not been shown to predict HCT
outcomes. For example, Niederwieser et al.80 analyzed data
from 19 patients with chronic myeloid leukemia given grafts
after 2 Gy TBI with or without fludarabine. Slow versus rapid
reduction of BCR/ABL transcripts after HCT was associated with
increased risk of relapse (P¼ 0.006), while low donor granulo-
cyte chimerism levels were not. Similarly, we failed to find any
association between donor granulocyte chimerism levels and
disease relapse in a study analyzing data from 120 patients given
nonmyeloablative conditioning.30 Similarly, donor chimerism
levels among total marrow cells have been a poor predictor of
HCT outcomes after nonmyeloablative conditioning,18 although
Figure 3 Cumulative incidence of relapse according to day-84 donor
T-cell chimerism levels in patients reported in ref.19 given grafts after
2 Gy TBI with or without fludarabine (P¼ 0.002).
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one study suggested higher risk of relapse in patients with mixed
donor/host marrow chimerism (57%) than in those with full
donor marrow chimerism (30%, P¼ 0.06) on day 30 after
reduced intensity conditioning.56 Nevertheless, serial chimerism
assessments in blood or marrow sub-populations enriched for
the malignant cell type (for example CD34þ cells in patients
with leukemia,41 CD19þ cells in patients with chronic
lymphocytic leukemia,43 or CD138þ cells in patients with
multiple myeloma42) might be able to better predict relapse/
progression after nonmyeloablative conditioning.
Disease-specific engraftment kinetics in nonmalignant
diseases
In patients with nonmalignant diseases, low levels of donor
chimerism among total blood or marrow cells, and particularly
among T- and NK-cells, have been associated with increased
risk of graft rejection, as observed in patients transplanted for
malignant disease (nicely reviewed by Bader et al.1). In addition,
assessment of disease-specific donor chimerism levels among
lymphocyte subsets or erythroid cells provided valuable
information that could affect clinical decisions in patients
transplanted for severe combined immunodeficiency (SCID)81
or sickle cell disease, respectively.82
Van Leeuwen et al.81 studied engraftment kinetics in 14
children with SCID given marrows after either no conditioning,
reduced-intensity conditioning, or a myeloablative regimen, and
surviving more than 1 year after HCT. While peripheral blood
T-cells were exclusively or predominantly of donor origin in all
children, B-, NK- and myeloid- cells were either of recipient,
donor or mixed origin. Interestingly, engraftment of donor NK
cells was associated with increased in vitro NK cell function in
children with defective NK cells before HCT.
Burroughs et al. studied data from 14 patients with SCID
(n¼ 3) or other immunodeficiency disorders (n¼ 11) given grafts
from either related (n¼ 7) or unrelated (n¼ 7) donors (Burroughs
et al., Blood 2005; 106: 134a (abstract)). Two patients had no
conditioning, while 12 were conditioned with 2 Gy TBI with or
without added fludarabine. Mixed or full donor chimerism
among T-cell and granulocytes was observed in 10 patients,
whereas four patients received a second graft because of T-cell
graft rejection (n¼ 1), low donor T-cell chimerism levels (n¼ 2)
or loss of granulocyte donor chimerism (n¼ 1).
Wu et al.82 analyzed donor chimerism levels among
peripheral blood mononuclear cells and erythrocyte-lineage
cells in four patients with sickle cell disease given allogeneic
grafts after reduced-intensity conditioning. Erythrocyte-lineage
chimerism was determined by b-globin RNA pyrosequencing.
Interestingly, all four patients had predominant to full replace-
ment of peripheral-blood erythrocytes with donor cells, and
significant clinical improvement, despite peripheral blood
monocyte cell donor chimerism levels ranging from 25 to
85% (median 50%).
Manipulation of immunosuppression and/or infusion of donor
cells according to donor chimerism levels
Given the accumulating data suggesting that patients at high risk
for graft rejection and relapse might be identified early after HCT
by T-cell and NK-cell chimerism assessment, research protocols
aimed at preventing those complications in patients with low
levels of donor chimerism have been developed.
Prevention of graft rejection after nonmyeloablative
conditioning
We reported data from 53 patients given DLI (median dose of
1 107 T-cells/kg) as treatment of persistent/progressive disease
or to increase donor chimerism after HCT following condition-
ing with 2 Gy TBI with or without fludarabine.83 Following DLI,
grades II, III and IV acute GVHD were seen in six, two and one
patient, respectively, while 10 patients developed extensive
chronic GVHD. Three of 16 patients who received DLI for low
or failing donor chimerism achieved full donor T-cell chimer-
ism, four remained stable mixed chimera, and nine (including
eight of 12 patients with donor T-cell chimerism levelo50% at
the time of DLI) eventually rejected their grafts (Figure 4a).
Therefore, we developed a research protocol evaluating safety
and efficacy of the administration of pentostatin (given at 4 mg/
m2 to decrease host-versus-graft reactions) followed 2 days later
by DLI (1 107 T-cells/kg) to reverse pending graft rejection.
The results of the first 10 patients treated have been summarized
recently (Sandmaier BM, et al., Blood 2004; 104(Part 1): 57a
(abstract)). Patients were given pentostatin 54–339 (median 91)
days after HCT. Median donor T-cell chimerism level before
pentostatin and DLI was 29.5 (range 5–38)%. Six of 10 patients
showed increases of donor T-cell chimerism levels ranging from
63 to 100% (one example is shown in Figure 4b). In the
remaining four patients, donor T-cell chimerism remained at
5–26% following DLI (none experienced graft rejection, but two
received a second HCT for low donor T-cell chimerism levels
and aplasia). Interestingly, five of six responding patients versus
0 of four nonresponding patients experienced grade II–IV acute
GVHD (P¼ 0.047). These preliminary observations suggested
that immunosuppression with pentostatin followed by DLI might
be more effective for conversion to full donor chimerism than
DLI alone in patients with low T-cell and/or NK cell chimerism
levels after HCT with nonmyeloablative conditioning.
Prevention of relapse after nonmyeloablative or
reduced-intensity conditioning
Based on the observations that full donor T-cell chimerism was
associated with increased graft-versus-tumor effects,12,19 several
groups of investigators evaluated the ability of DLI to convert
mixed to full donor T-cell chimerism. Dey et al.28 analyzed
efficacy of prophylactic DLI (1 107 T-cells/kg) given 5 weeks
after HCT, in 16 patients given marrows from HLA-identical
related donors after conditioning with cyclophosphamide (150–
200 mg/kg), ATG and thymic irradiation. By day 100 after HCT,
10 patients had converted to full donor T-cell chimerism, two
had stable or increased donor chimerism levels, and four had
rejected their marrows (including four of four patients with
donor T-cell chimerism levels o25% before DLI). DLI were
complicated by grade III or grade IV acute GVHD in one and
four patients, respectively.
Peggs et al.84 analyzed the efficacy of dose-escalating DLI
given in 46 patients as treatment of persistent/progressive
disease or to convert mixed donor chimerism to full donor
T-cell chimerism in order to prevent relapse/progression. The
conditioning regimen used before HCT consisted of fludarabine
(150 mg/m2), melphalan (140 mg/m2), and alemtuzumab
(100 mg),84 and DLI were given at a starting dose of 1 106
T-cells/kg. Increasing doses were given at 3-month intervals
(3 106, 1 107, 3 107 and 1 108 T-cells/kg) in the absence
of GVHD if mixed chimerism or underlying malignancy
persisted. Grades II–IV GVHD occurred in five of 32 (16%)
(including three grade IV) sibling and seven of 14 (50%)
(including four grade IV) unrelated donor recipients (P¼ 0.002).
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Among 14 patients given DLI for mixed donor/host T-cell
chimerism, 12 were evaluable for chimerism responses, and
10 of 12 achieved full donor T-cell chimerism.
Chimerism assessment for patients with disease relapse
Chimerism assessment has also been useful in patients with
relapsed hematological malignancies after nonmyeloablative
HCT. Chimerism analyses included both flow-sorted malignant
cells, to determine whether the disease originated in cells of
donor85,86 or host origin, and T-cells, to rule out concomitant
graft rejection. Donor lymphocyte infusions, with or without
preceding chemotherapy, were considered in patients with
sustained donor engraftment and recurrent hematological
malignancy in cells of host origin83 whereas different strategies,
such as second HCT or disease-targeted therapies, were
considered for other patients.
Summary and conclusion
Engraftment kinetics after nonmyeloablative or reduced-inten-
sity conditioning have depended on the intensity of pretrans-
plant chemotherapy, the intensity of the conditioning regimens,
the graft composition, and the postgrafting immunosuppression.
Monitoring mixed chimerism among peripheral blood sub-
populations early after transplantation identifies patients at risk
for graft rejection and for grade II–IV acute GVHD. Achievement
of full donor T-cell chimerism is associated with decreased risk
of relapse. Further, preliminary observations suggest that high
levels of NK-cell donor chimerism early after HCT might predict
better progression-free survival. Chimerism levels among
granulocytes have been poor predictors for HCT outcomes,
but further studies are needed to evaluate the efficacy of
chimerism monitoring among cell subtypes enriched for the
phenotype of the malignant cells. In addition, the impact of
donor chimerism levels among other cell sub-types (such as
dendritic cells,87,88 Langerhans cells,89 plasmacytoid dendritic
cells,90 mesenchymal cells,91 or regulatory T-cells92) on HCT
outcomes after nonmyemoablative conditioning deserves further
investigation. Finally, in patients with hematological relapse
after HCT, assessing the origin of both malignant cells and
T-cells might assist in determining the best therapeutic options.
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